These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31176273)

  • 1. Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
    Gori S; Barberis M; Bella MA; Buttitta F; Capoluongo E; Carrera P; Colombo N; Cortesi L; Genuardi M; Gion M; Guarneri V; Incorvaia L; La Verde N; Lorusso D; Marchetti A; Marchetti P; Normanno N; Pasini B; Pensabene M; Pignata S; Radice P; Ricevuto E; Sapino A; Tagliaferri P; Tassone P; Trevisiol C; Truini M; Varesco L; Russo A;
    Crit Rev Oncol Hematol; 2019 Aug; 140():67-72. PubMed ID: 31176273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies.
    Russo A; Incorvaia L; Capoluongo E; Tagliaferri P; Gori S; Cortesi L; Genuardi M; Turchetti D; De Giorgi U; Di Maio M; Barberis M; Dessena M; Del Re M; Lapini A; Luchini C; Jereczek-Fossa BA; Sapino A; Cinieri S;
    ESMO Open; 2022 Jun; 7(3):100459. PubMed ID: 35597177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic testing in ovarian cancer - clinical impact and current practices.
    Knabben L; Imboden S; Mueller MD
    Horm Mol Biol Clin Investig; 2019 Oct; 41(3):. PubMed ID: 31577534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
    Flaum N; Morgan RD; Burghel GJ; Bulman M; Clamp AR; Hasan J; Mitchell CL; Badea D; Moon S; Hogg M; Hadjiyiannakis D; Clancy T; Schlecht H; Woodward ER; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Lalloo FI; Harkness EF; Evans DGR
    Eur J Hum Genet; 2020 Nov; 28(11):1541-1547. PubMed ID: 32651552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [BRCA diagnostics of ovarian cancer : Molecular tumor testing since the introduction of PARP inhibitor therapy].
    Löser H; Heydt C; Büttner R; Markiefka B
    Pathologe; 2017 Mar; 38(2):117-126. PubMed ID: 28258387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
    Moschetta M; George A; Kaye SB; Banerjee S
    Ann Oncol; 2016 Aug; 27(8):1449-55. PubMed ID: 27037296
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Talwar V; Rauthan A
    Indian J Cancer; 2022 Mar; 59(Supplement):S56-S67. PubMed ID: 35343191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
    Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
    Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finding all BRCA pathogenic mutation carriers: best practice models.
    Hoogerbrugge N; Jongmans MC
    Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S19-26. PubMed ID: 27514840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
    Vošmiková H; Ryška A; Sieglová K; Laco J
    Cesk Patol; 2016; 52(4):210-214. PubMed ID: 27869447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The first Japanese nationwide multicenter study of
    Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
    Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM).
    Gadducci A; Aletti GD; Landoni F; Lazzari R; Mangili G; Olivas P; Pignata S; Salutari V; Sartori E; Scambia G; Zannoni GF; Sabbatini R; Lorusso D
    Tumori; 2021 Apr; 107(2):100-109. PubMed ID: 33106117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
    Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
    Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
    BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.
    Capoluongo E; Ellison G; López-Guerrero JA; Penault-Llorca F; Ligtenberg MJL; Banerjee S; Singer C; Friedman E; Markiefka B; Schirmacher P; Büttner R; van Asperen CJ; Ray-Coquard I; Endris V; Kamel-Reid S; Percival N; Bryce J; Röthlisberger B; Soong R; de Castro DG
    Semin Oncol; 2017 Jun; 44(3):187-197. PubMed ID: 29248130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
    Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
    Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    Pujol P; Barberis M; Beer P; Friedman E; Piulats JM; Capoluongo ED; Garcia Foncillas J; Ray-Coquard I; Penault-Llorca F; Foulkes WD; Turnbull C; Hanson H; Narod S; Arun BK; Aapro MS; Mandel JL; Normanno N; Lambrechts D; Vergote I; Anahory M; Baertschi B; Baudry K; Bignon YJ; Bollet M; Corsini C; Cussenot O; De la Motte Rouge T; Duboys de Labarre M; Duchamp F; Duriez C; Fizazi K; Galibert V; Gladieff L; Gligorov J; Hammel P; Imbert-Bouteille M; Jacot W; Kogut-Kubiak T; Lamy PJ; Nambot S; Neuzillet Y; Olschwang S; Rebillard X; Rey JM; Rideau C; Spano JP; Thomas F; Treilleux I; Vandromme M; Vendrell J; Vintraud M; Zarca D; Hughes KS; Alés Martínez JE
    Eur J Cancer; 2021 Mar; 146():30-47. PubMed ID: 33578357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
    Vos S; van Diest PJ; Moelans CB
    Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
    J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.